泽璟制药公告，公司自主研发的盐酸吉卡昔替尼片(泽普平)获国家药品监督管理局批准上市，适用于中 危或高危原发性骨髓纤维化等疾病的成人患者。该药品为1类新药，通过抑制JAK-STAT信号传导通路减 少炎症和脾脏肿大。根据III期临床试验，治疗24周时脾脏体积较基线缩小≥35%的受试者比例为72.3%， 显示良好获益。盐酸吉卡昔替尼片还被纳入《中国临床肿瘤学会(CSCO)恶性血液病诊疗指南2024》中 骨髓纤维化一线分层治疗的I级推荐。 ...

Core Viewpoint - The Chinese innovative pharmaceutical sector is gaining international recognition, highlighted by significant deals and promising clinical data, leading to increased interest in related ETFs [1][3][4]. Group 1: Market Performance - The innovative drug ETF (517110) has rebounded nearly 15% since early April, reflecting strong performance in the pharmaceutical sector [1]. - The biopharmaceutical ETF and vaccine ETF also showed positive movements, with respective increases of 1.17% and 0.89% [2]. Group 2: ASCO Conference Insights - At the 2025 ASCO conference, over 70 research outcomes from Chinese pharmaceutical companies were presented, showcasing advancements in ADC and bispecific antibody technologies [3]. - Notable performances include Zai Lab's ZG005 and Huahai Pharmaceutical's HB0025, which exceeded expectations in early clinical trials for cervical and endometrial cancers, respectively [3]. Group 3: Business Development Trends - Recent business development (BD) activities in the innovative drug sector have seen record-breaking upfront payments, such as the $12.5 billion upfront payment from Pfizer for a PD-1/VEGF bispecific antibody from 3SBio [4][7]. - The increase in upfront payments and total deal values indicates growing international recognition of Chinese innovative drugs [7]. Group 4: Future Outlook - The innovative drug sector is expected to benefit from ongoing BD transactions, advancements in artificial intelligence across the pharmaceutical value chain, and the implementation of new healthcare policies [7]. - The overall sentiment and valuation in the pharmaceutical sector may improve due to domestic policy optimizations and a recovery in medical equipment procurement [7].

Core Viewpoint - The report highlights the performance and holdings of the Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A, indicating a recent decline in net value but strong returns over various time frames [1]. Fund Performance - The latest net value of the fund is 1.5670 yuan, reflecting a decrease of 1.94% - Over the past month, the fund achieved a return of 3.91%, ranking 171 out of 1959 in its category - In the last three months, the fund's return was 22.33%, ranking 5 out of 1950 - Year-to-date, the fund has returned 30.15%, ranking 17 out of 1943 [1]. Fund Holdings - The top ten stock holdings of the fund account for a total of 64.17%, with the following allocations: - Heng Rui Medicine: 10.23% - Kelun Pharmaceutical: 9.09% - Baile Tianheng: 8.94% - Haizike: 8.27% - Xinlitai: 6.66% - Zai Jian Pharmaceutical-U: 6.10% - Xin Nuo Wei: 4.69% - Rongchang Biotechnology: 3.49% - Nuocheng Jianhua-U: 3.35% - Microelectrophysiology: 3.35% [1]. Fund Background - The Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A was established on June 18, 2015, and as of March 31, 2025, it has a total scale of 4.408 billion yuan - The fund manager is Zhang Wei, who has extensive experience in the pharmaceutical sector [1][2].

金融界2025年5月26日消息，工银前沿医疗股票A(001717) 最新净值2.9540元，下跌1.86%。该基金近1个 月收益率4.79%，同类排名62|864；近3个月收益率9.08%，同类排名51|853；今年来收益率12.28%，同 类排名93|850。 工银前沿医疗股票A股票持仓前十占比合计59.05%，分别为：恒瑞医药（10.11%）、科伦药业 （8.01%）、药明康德（7.72%）、百济神州-U（6.85%）、信立泰（4.90%）、泽璟制药-U （4.77%）、鱼跃医疗（4.60%）、新诺威（4.36%）、华东医药（4.20%）、海思科（3.53%）。 来源：金融界 公开资料显示，工银前沿医疗股票A基金成立于2016年2月3日，截至2025年3月31日，工银前沿医疗股 票A规模90.81亿元，基金经理为赵蓓。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月 ...

Core Viewpoint - The article discusses the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, highlighting its recent net value, returns, and top holdings [1]. Fund Performance - The latest net value of the ICBC Medical Healthcare Stock Fund is 2.5580 yuan, reflecting a decrease of 1.16% - The fund's return over the past month is 3.52%, ranking 172 out of 940 in its category - Over the last six months, the return is 9.79%, with a ranking of 202 out of 914 - Year-to-date, the return stands at 12.24%, ranking 98 out of 926 [1]. Fund Holdings - The top ten holdings of the ICBC Medical Healthcare Stock Fund account for a total of 39.79%, with the following key positions: - Heng Rui Medicine: 8.90% - WuXi AppTec: 5.12% - Aier Eye Hospital: 4.94% - BeiGene: 3.77% - Zai Lab: 3.52% - New Horizon Health: 3.27% - Mindray Medical: 2.80% - Yuwell Medical: 2.76% - United Imaging Healthcare: 2.47% - Innovent Biologics: 2.24% [1]. Fund Management - The ICBC Medical Healthcare Stock Fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [1][2].

证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 国产创新药闪耀 ASCO 国际舞台 2025 年 05 月 25 日 增持（维持） [Table_Tag] [Table_Summary] 投资要点 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -18% -15% -12% -9% -6% -3% 0% 3% 6% 9% 12% 15% 2024/5/27 2024/9/24 2025/1/22 2025/5/22 医药生物 沪深300 相关研究 《三抗药物研发进入快车道，建议关 注泽璟制药、三生制药等》 2025-05-18 | 1. 本周及年初至今各医药股收益情况 4 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2. 中国创新药闪耀 ASCO 会议，口头报告数量再创新高 7 | | | | | | | | | 2.1. 2025 ASCO 摘要披露，众多国产抗体和 ADC 类分子亮相口头报告 7 | | | | | | | | | 后线治疗不断迎 ...

公开资料显示，工银前沿医疗股票C基金成立于2020年11月23日，截至2025年3月31日，工银前沿医疗 股票C规模13.80亿元，基金经理为赵蓓。 金融界2025年5月21日消息，工银前沿医疗股票C(010685) 最新净值2.9140元，增长1.53%。该基金近1个 月收益率4.11%，同类排名420|1001；近3个月收益率9.30%，同类排名81|988；今年来收益率13.47%， 同类排名116|978。 工银前沿医疗股票C股票持仓前十占比合计59.05%，分别为：恒瑞医药（10.11%）、科伦药业 （8.01%）、XD药明康（7.72%）、百济神州-U（6.85%）、信立泰（4.90%）、泽璟制药-U （4.77%）、鱼跃医疗（4.60%）、新诺威（4.36%）、华东医药（4.20%）、海思科（3.53%）。 来源：金融界 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The development of trispecific antibodies (TsAbs) is accelerating, with a focus on companies such as Zai Lab and Sanofi [18]. - The report highlights the performance of various sub-sectors within the industry, ranking them as follows: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [12][13]. Summary by Sections Industry Performance - The A-share pharmaceutical index has increased by 1.3% this week and 2.5% year-to-date, outperforming the CSI 300 by 0.2% and 3.6% respectively [11]. - The H-share biotechnology index has shown a 0.3% increase this week and a 27.8% increase year-to-date, outperforming the Hang Seng Technology Index by -1.7% and 9.6% respectively [11]. Specific Company Recommendations - From a growth perspective, the report recommends focusing on innovative drug companies such as Zai Lab, Sanofi, and others [13]. - For undervalued stocks, it suggests looking into traditional Chinese medicine companies like Zai Lab and Dong-E E-Jiao [13]. - High dividend yield stocks are recommended from the traditional Chinese medicine sector, including Jiangzhong Pharmaceutical and Yunnan Baiyao [13]. Trispecific Antibodies Development - TsAbs are engineered antibodies capable of binding to three different antigen targets, offering enhanced therapeutic potential in cancer immunotherapy [18]. - Currently, no TsAbs have been approved for market, but several companies, including Zai Lab and Sanofi, are actively developing these therapies [18][32]. Clinical Progress - The report outlines the clinical stages of various TsAbs, noting that Zai Lab's ZG006 is among the leading candidates in clinical trials [32]. - Other notable candidates include those from companies like Sanofi and IBI3003 from Innovent Biologics, which are also in advanced clinical stages [32].

Core Viewpoint - The company intends to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency and generate additional returns while ensuring the safety of the raised funds and the implementation of investment projects [1][2][6]. Fundraising Basic Situation - The company was approved to publicly issue 60,000,000 A shares at a price of RMB 33.76 per share, raising a total of RMB 2,025,600,000, with a net amount of RMB 1,908,220,754.68 after deducting related fees [1]. - Additionally, the company was authorized to issue shares to specific targets, raising RMB 1,199,999,955.00, with a net amount of RMB 1,181,933,181.59 after deducting issuance costs [2]. Cash Management Plan - The company plans to use up to RMB 4 billion from the idle funds raised from the initial public offering and up to RMB 8.5 billion from the funds raised from the specific target issuance for cash management [3][4]. - The investment will focus on low-risk, high-liquidity financial products, including but not limited to structured deposits and time deposits, with a maximum investment period of one year [3][4]. Decision Validity and Disclosure - The decision to use idle funds for cash management is valid for 12 months from June 15, 2025, and the company will comply with information disclosure obligations as per regulatory requirements [4][5]. - The income generated from cash management will be prioritized for supplementing investment project funding and daily operational liquidity [4]. Impact on Daily Operations - The cash management plan will not affect the normal operation of the company's investment projects or its main business activities, while also potentially enhancing overall performance and shareholder returns [4][5]. Risk Control Measures - The company has established a risk control framework for cash management, including selecting quality banks and monitoring investment performance to mitigate potential risks [5][6]. - The company will ensure compliance with relevant regulations and maintain a separation of decision-making, execution, and supervision functions in cash management activities [5][6]. Review Procedures - The board of directors approved the cash management plan, which does not require shareholder meeting approval, ensuring adherence to necessary procedures [6][7].

| 证券代码：688266 | | 证券简称：泽璟制药 | | | | 公告编号：2025-020 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 苏州泽璟生物制药股份有限公司 | | | | | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | | | | | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | | | | | 重要内容提示： | | | | | | | | | | | 本次会议是否有被否决议案：无 | ? | | | | | | | | | | 会议召开和出席情况 | 一、 | | | | | | | | | | 股东大会召开的时间：2025 5 | （一） | 年 | 月 16 | 日 | | | | | | | 股东大会召开的地点：昆山皇冠国际会展酒店（江苏省昆山市前进西路 | （二） | | | | | | | | | | 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股 ...